RxDoctor Payments Data

Muhammad Shaaban, MD

Family Medicine · Panama City, FLNPI 1801275276

Payments from drug & device makers

$734in general payments, 2019–2025

Across 33 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$244
  • Pfizer$154
  • Exact Sciences$89
  • Lilly USA, LLC$73
  • AstraZeneca$60
  • Novo Nordisk$41
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$217,799
Medicare patients
876
Services billed
3,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$12,329
MounjaroTirzepatide12$12,318
ShingrixVaricella-Zoster Ge/As01b/Pf30$6,717
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf26$1,834
Levothyroxine Sodium71$871
Gabapentin29$704
Atorvastatin Calcium49$673
Testosterone Cypionate12$597
Cefdinir32$459
Omeprazole31$409
Bupropion XlBupropion Hcl12$391
Albuterol Sulfate HfaAlbuterol Sulfate12$359
Rosuvastatin Calcium32$357
Doxycycline Hyclate39$332
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$12,32913 claims
Lilly USA, LLCMounjaro$73$12,31812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →